

Acinetobacter baumannii
(n=2,733 from 73 Hospitals)

	% Susceptible (IQR)	Number of Isolates	Number of Hospitals
Ampicillin-Sulbactam	37% (27-62)	2,470	70
Piperacillin-Tazobactam	35% (20-48)	1,381	61
Ceftriaxone	13 % (4-24)	2,073	54
Ceftazidime	33% (27-52)	2,386	63
Cefepime	32 % (19-55)	2,338	60
Doripenem	51% (33-67)	78	5
Imipenem	43% (33-64)	601	35
Meropenem	37% (24-65)	2,188	57
Amikacin	36% (25-67)	1,888	51
Gentamicin	38% (33-62)	2,614	73
Tobramycin	40% (37-66)	2,235	63
Ciprofloxacin	28% (25-54)	2,384	64
Levofloxacin	28% (25-55)	2,278	63
Trimethoprim/Sulfamethoxazole	43% (42-70)	2,546	73
Minocycline	59% (56-86)	266	16

Citrobacter freundii
(n=3,063 from 64 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Piperacillin-Tazobactam	84% (78-90)	3,023	63
Ceftriaxone	78% (72-83)	2,978	61
Ceftazidime	80% (72-84)	2,704	58
Cefepime	98% (96-100)	3,006	61
Doripenem	100% (100-100)	96	5
Ertapenem	99% (100-100)	2,491	42
Imipenem	96% (93-100)	687	27
Meropenem	100% (100-100)	2,793	54
Amikacin	100% (100-100)	2,614	59
Gentamicin	92% (86-100)	3,073	64
Tobramycin	90% (86-100)	1,428	55
Ciprofloxacin	91% (80-96)	2,726	56
Levofloxacin	86% (86-96)	1,400	53
Trimethoprim/Sulfamethoxazole	83% (76-91)	3,057	64
Nitrofurantoin	93% (88-100)	2,341	62

Citrobacter koseri
(n=1,409 from 54 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ampicillin-Sulbactam	37% (67-100)	491	18
Piperacillin-Tazobactam	98% (97-100)	1,404	53
Ceftriaxone	97% (95-100)	1,345	49
Ceftazidime	96% (96-100)	990	46
Cefepime	99% (100-100)	1,237	49
Ertapenem	100% (100-100)	790	32
Doripenem	100% (100-100)	106	4
Imipenem	100% (100-100)	615	24
Meropenem	100% (100-100)	1,175	42
Amikacin	100% (100-100)	929	45
Gentamicin	99% (100-100)	1,411	53
Tobramycin	99% (100-100)	1,247	50
Ciprofloxacin	97% (96-100)	1,066	44
Levofloxacin	98% (100-100)	1,299	49
Trimethoprim/Sulfamethoxazole	97% (97-100)	1,398	54
Nitrofurantoin	85% (80-94)	1,040	51

***Enterobacter cloacae* complex**
(n=7,500 from 71 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Piperacillin-Tazobactam	79% (72-82)	7,347	63
Ceftriaxone	74% (65-79)	7,021	64
Ceftazidime	78% (69-80)	6,397	62
Cefepime	93% (89-98)	7,268	67
Ertapenem	95% (86-100)	5,408	43
Doripenem	97% (96-99)	291	5
Imipenem	96% (96-100)	1,534	27
Meropenem	99% (98-100)	6,820	60
Amikacin	99% (100-100)	6,523	66
Gentamicin	97% (96-100)	7,468	70
Tobramycin	95% (94-100)	4,029	60
Ciprofloxacin	95% (90-98)	6,582	61
Levofloxacin	94% (93-100)	3,643	56
Trimethoprim/Sulfamethoxazole	89% (83-92)	7,501	71
Nitrofurantoin	33% (21-41)	4,296	64

Escherichia coli
(n=190,079 from 81 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ampicillin-sulbactam	58% (48-56)	163,214	72
Piperacillin-Tazobactam	95% (93-95)	189,992	81
Ceftriaxone	87% (74-85)	186,017	77
Ceftazidime	91% (75-92)	171,649	60
Cefepime	91% (75-96)	172,314	75
Cefazolin	86% (71-85)	156,696	55
Doripenem	99% (99-100)	7,141	5
Ertapenem	99% (99-100)	151,672	51
Imipenem	99% (99-100)	32,425	39
Meropenem	99% (99-100)	175,118	65
Amikacin	99% (99-100)	170,120	79
Gentamicin	88% (83-89)	189,804	80
Tobramycin	85% (80-88)	72,142	69
Ciprofloxacin	76% (57-72)	175,790	74
Levofloxacin	67% (57-74)	66,930	67
Trimethoprim/Sulfamethoxazole	71% (62-69)	190,179	81
Nitrofurantoin	96% (95-97)	172,666	74

Klebsiella (Enterobacter) aerogenes
(n=5,362 from 71 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Piperacillin-Tazobactam	81% (70-85)	5,291	70
Ceftriaxone	80% (65-83)	5,219	67
Ceftazidime	81% (68-83)	4,352	63
Cefepime	96% (94-100)	5,047	66
Doripenem	100% (100-100)	192	5
Ertapenem	97% (96-100)	4,156	44
Imipenem	84% (74-100)	1,004	27
Meropenem	98% (98-100)	4,954	59
Amikacin	99% (100-100)	4,856	65
Gentamicin	97% (95-100)	5,342	70
Tobramycin	94% (95-100)	2,329	59
Ciprofloxacin	95% (92-100)	4,793	61
Levofloxacin	90% (92-100)	2,269	56
Trimethoprim/Sulfamethoxazole	95% (93-100)	5,346	71
Nitrofurantoin	15% (8-27)	3,719	65

Klebsiella oxytoca
(n=4,842 from 70 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ampicillin-Sulbactam	57% (52-71)	4,189	63
Piperacillin-Tazobactam	89% (86-96)	4,831	70
Ceftriaxone	89% (82-94)	4,752	66
Ceftazidime	93% (88-97)	4,329	62
Cefepime	94% (88-100)	4,387	65
Doripenem	100% (100-100)	162	4
Ertapenem	98% (100-100)	3,774	44
Imipenem	95% (98-100)	1,104	26
Meropenem	99% (100-100)	4,394	59
Amikacin	98% (100-100)	4,304	63
Gentamicin	93% (89-98)	4,817	69
Tobramycin	90% (88-97)	2,404	59
Ciprofloxacin	93% (89-100)	4,461	61
Levofloxacin	91% (90-100)	2,177	54
Trimethoprim/Sulfamethoxazole	87% (83-92)	4,829	70
Nitrofurantoin	76% (78-94)	3,244	67

Klebsiella pneumoniae
(n=35,781 from 81 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ampicillin-Sulbactam	76% (63-78)	30,645	73
Piperacillin-Tazobactam	89% (81-91)	35,771	81
Ceftriaxone	85% (73-87)	34,994	77
Ceftazidime	87% (76-87)	31,634	73
Cefepime	90% (77-93)	31,827	75
Cefazolin	88% (73-87)	26,376	46
Doripenem	96% (96-99)	1,220	5
Ertapenem	97% (96-100)	26,669	51
Imipenem	92% (90-98)	7,615	38
Meropenem	97% (90-99)	32,730	71
Amikacin	97% (92-99)	31,708	79
Gentamicin	91% (84-93)	35,725	80
Tobramycin	83% (79-90)	17,132	69
Ciprofloxacin	86% (71-86)	31,898	72
Levofloxacin	81% (71-90)	15,879	66
Trimethoprim/Sulfamethoxazole	83% (76-85)	35,783	81
Nitrofurantoin	25% (25-34)	28,867	80

Morganella morganii
(n=3,788 from 70 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ampicillin-Sulbactam	11% (3-15)	2,267	57
Piperacillin-Tazobactam	94% (93-100)	3,792	70
Ceftriaxone	80% (73-90)	3,660	66
Ceftazidime	78% (69-86)	3,547	63
Cefepime	94% (94-100)	3,602	65
Doripenem	91% (89-98)	65	3
Ertapenem	97% (100-100)	2,893	43
Imipenem	59% (20-92)	967	24
Meropenem	98% (100-100)	3,365	58
Amikacin	97% (99-100)	3,470	65
Gentamicin	75% (70-82)	3,791	69
Tobramycin	83% (85-97)	2,101	59
Ciprofloxacin	64% (40-72)	3,397	61
Levofloxacin	54% (47-75)	2,057	57
Trimethoprim/Sulfamethoxazole	61% (49-68)	3,796	70

Proteus mirabilis
(n=23,042 from 81 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ampicillin-Sulbactam	78% (73-82)	11,211	69
Piperacillin-Tazobactam	97% (97-100)	23,047	81
Ceftriaxone	90% (80-91)	22,338	77
Ceftazidime	94% (85-96)	20,605	67
Cefepime	93% (85-96)	20,462	75
Cefazolin	88% (72-88)	17,505	52
Doripenem	96% (97-100)	470	4
Ertapenem	99% (100-100)	16,671	52
Imipenem	59% (17-93)	2,360	21
Meropenem	99% (99-100)	20,126	67
Amikacin	99% (99-100)	20,484	78
Gentamicin	87% (78-88)	22,983	80
Tobramycin	84% (81-90)	11,376	69
Ciprofloxacin	75% (43-71)	21,026	73
Levofloxacin	63% (54-73)	10,912	66
Trimethoprim/Sulfamethoxazole	73% (58-74)	23,030	81

Pseudomonas aeruginosa
(n=26,279 from 81 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Piperacillin-Tazobactam	86% (79-90)	25,897	68
Ceftazidime	84% (73-88)	24,215	75
Cefepime	85% (74-88)	25,493	78
Doripenem	89% (87-92)	1,265	5
Imipenem	75% (62-84)	6,355	41
Meropenem	87% (74-90)	23,843	71
Amikacin	96% (95-99)	16,952	79
Gentamicin	86% (82-92)	26,467	80
Tobramycin	92% (92-97)	16,357	63
Ciprofloxacin	79% (65-83)	23,563	74
Levofloxacin	69% (63-77)	14,142	68

Serratia marcescens
(n=4,044 from 69 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Piperacillin-Tazobactam	89% (79-98)	2,940	50
Ceftriaxone	86% (80-95)	3,890	64
Ceftazidime	91% (76-100)	3,679	62
Cefepime	92% (86-100)	3,809	64
Doripenem	100% (100-100)	138	4
Ertapenem	97% (100-100)	2,758	42
Imipenem	80% (88-100)	654	16
Meropenem	98% (97-100)	3,601	56
Amikacin	94% (96-100)	3,681	63
Gentamicin	96% (97-100)	4,050	68
Tobramycin	83% (76-93)	2,482	56
Ciprofloxacin	84% (66-94)	3,609	59
Levofloxacin	83% (75-97)	2,369	58
Trimethoprim/Sulfamethoxazole	96% (94-100)	3,882	61

Stenotrophomonas maltophilia
(n=2,469 from 75 Hospitals)

	% Susceptible (IQR)	Number of Isolates tested	Number of hospitals
Ceftazidime	41% (23-61)	1,586	39
Levofloxacin	81% (78-91)	2,448	73
Trimethoprim/Sulfamethoxazole	93% (89-100)	2,467	75
Minocycline	99% (99-100)	1,012	17

